Optimizing Levothyroxine Replacement: A Precision Dosage Model for Post-Thyroidectomy Patients

Area of Science:

• Endocrinology
• Oncology
• Clinical Chemistry

Background:

• Thyroidectomy for thyroid tumors frequently leads to hypothyroidism, necessitating levothyroxine (LT4) hormone replacement.
• Achieving optimal LT4 dosage is critical for maintaining normal hormone levels and suppressing TSH in cancer patients, yet it remains a clinical challenge.
• Suboptimal LT4 dosing can result in uncertain treatment outcomes and adverse side effects.

Purpose of the Study:

• To identify key clinical and laboratory variables that predict optimal levothyroxine (LT4) dosage in patients following total thyroidectomy.
• To develop a predictive model for LT4 dosage to enhance treatment efficacy and patient management post-thyroidectomy.

Main Methods:

• Analysis of clinical and laboratory data from 510 total thyroidectomy patients.
• Application of data preprocessing, Principal Component Analysis, correlation, and regression analyses on 274 samples with 98 variables using R.
• Identification of significant factors influencing satisfactory LT4 tablet dosage.

Main Results:

• Eight variables significantly impacted optimal LT4 dosage: benign/malignant status, electrophoretic albumin ratio (BQB), total protein (TP), fibrin degradation products (FDP), thyroid-stimulating hormone receptor antibody (TRAB_1), prothrombin time (PT), monocyte count (MONO#), and hepatitis C antibody (HCV0C).
• A predictive linear model was established based on these significant variables.

Conclusions:

• Patient characteristics such as benign/malignant status, TRAB_1, and BQB ratio serve as valuable indicators for guiding postoperative LT4 dosage.
• The developed linear model offers a tool for predicting LT4 dosage, potentially improving treatment effectiveness and optimizing resource utilization in thyroidectomy patients.